All In Biotech

Drug Trial Radar · NCT05541016

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy

Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

455

Planned (sponsor's estimate)

Start

Mar 20, 2023

Primary completion

Sep 6, 2029

Study completion Sep 6, 2029

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial examines the use of blood-based biomarkers is to help inform decision making for treatment and radiation therapy for patients with human papillomavirus (HPV) positive oropharyngeal squamous cell cancers. The standard treatments for head and neck cancers are radiation therapy with chemotherapy or surgery potentially followed by radiation therapy with or without chemotherapy. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving chemotherapy along with radiation may kill more tumor cells. However, the cancer can recur or can spread to other parts of the body and all treatments can be associated with side effects. The purpose of this study is to evaluate a blood-based biomarker, using the NavDx testing device, for head and neck cancers in order to see if it can help improve selection of the intensity of treatment in order to best balance the side effects of treatment with the goal of decreasing cancer recurrence. This test could aid in early detection of recurrence and salvage therapy.

Conditions

  • Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
  • Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma
  • Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
  • Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and saliva specimen collection for NavDx testing

  • CisplatinDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • Diffusing Alpha-emitter Radiation TherapyRadiation

    Undergo DART

  • DocetaxelDrug

    Given IV

  • Intensity-Modulated Proton TherapyProcedure

    Undergo IMPT

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo IMRT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Modified Barium Swallow StudyProcedure

    Undergo MBSS

  • Observation ActivityOther

    Undergo observation

  • Positron Emission TomographyProcedure

    Undergo PET scan

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • QuestionnaireOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: From registration to the first of either disease progression/recurrence or death, assessed up to 5 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona · Recruiting

  • Mayo Clinic in Florida

    Jacksonville, Florida · Recruiting

  • Mayo Clinic in Rochester

    Rochester, Minnesota · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.